- Home
- FMST vs RDHL Comparison
FMST vs RDHL Comparison
Compare FMST & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FMST | RDHL |
|---|---|---|
| Founded | 2005 | 2009 |
| Country | Canada | Israel |
| Employees | N/A | N/A |
| Industry | Other Metals and Minerals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.3M | 3.3M |
| IPO Year | 2022 | 2012 |
Fundamental Metrics
Financial Performance| Metric | FMST | RDHL |
|---|---|---|
| Price | $0.62 | $0.48 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 86.1K | ★ 209.2K |
| Earning Date | 11-12-2026 | 09-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $17,592.31 |
| Revenue Next Year | N/A | $25.89 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.64 | $0.48 |
| 52 Week High | $4.57 | $2.26 |
Technical Indicators
Market Signals| Indicator | FMST | RDHL |
|---|---|---|
| Relative Strength Index (RSI) | 29.83 | 34.08 |
| Support Level | N/A | N/A |
| Resistance Level | $0.90 | $1.07 |
| Average True Range (ATR) | 0.07 | 0.03 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 7.69 | 12.97 |
Price Performance
Historical ComparisonAbout FMST Foremost Lithium Resource & Technology Ltd.
Foremost Clean Energy Ltd is an exploration company focused on the identification and development of high potential mineral opportunities in stable jurisdictions. Its Uranium properties includes Eastern Athabasca, and Blue-Sky. Its Lithium properties includes Zoro Lithium Project, JEAN LAKE LITHIUM GOLD PROJECT, Peg North Project, Grass River Claims Project, and JOL LITHIUM PROJECT.
About RDHL Redhill Biopharma Ltd.
RedHill Biopharma Ltd is a specialty biopharmaceutical company mainly focused on the U.S. development and commercialization of drugs for GI diseases, infectious diseases, and oncology. The Company is mainly focused on the advancement of its development pipeline of clinical-stage therapeutic candidates and also commercializes its GI-related product, Talicia (omeprazole, amoxicillin, and rifabutin) in the U.S. Its therapeutic candidates include opaganib, RHB-204, RHB-104, RHB-102 (Bekinda), and RHB-107.